In-office compounding of lidocaineepinephrine: An option for anesthesia preparation before skin biopsy To the Editor: In-office compounding of local anesthesia is a common practice in outpatient dermatology offices. Compounding is the process of combining $2 prescribed drugs to tailor medications to individual patient needs. Lidocaine hydrochloride 1% with epinephrine 1:100,000 represents a common anesthetic preparation. 1 Premixed lidocaine with epinephrine is acidic, so it produces significant pain upon injection. Adding 8.4% sodium bicarbonate neutralizes the pH of the solution and reduces injection pain. 2 Risks associated with pharmacy compounding have been highlighted in the media recently after a 2012 outbreak of fungal infections was linked to pharmacy compounding of methylprednisolone acetate resulting in multiple cases of meningitis. 3 The US Pharmacopeia compounding provisions establish that in-office compounding for dermatologic procedures should require sterile preparation with properly garbed personnel and near-immediate use of compounded lidocaine preparations. In outpatient settings, however, compounding typically takes place in nonsterile settings.
The type and frequency of adverse events associated with in-office compounded anesthetic injections is poorly characterized. In this study, we aim to assess the risk and character of adverse events associated with in-office compounding of local anesthesia with sodium bicarbonate in an outpatient academic dermatology facility.
We reviewed the charts of 100 randomly selected patients with biopsies performed using 1-3 mL of 1% lidocaine and 1:100,000 epinephrine compounded with 8.4% sodium bicarbonate anesthesia during January 6, 2015-March 2, 2017. Data collected included patient age, sex, date of procedure, and any adverse events within 14 days of biopsy. Only patients with clinical follow-up after the biopsy were included in our study.
The ages of patients included in our study ranged 30-93 years, with a mean age of 72 years. Male patients accounted for 66 of the biopsies, and 34 included patients were female. Out of the 100 biopsies performed, 1 adverse event was noted. Seven days after a biopsy of the left lateral sidewall of the nose, the patient complained of stinging and burning of the biopsy site. No evidence of infection was noted upon clinical exam of the biopsy site. Mohs surgery was performed on the invasive squamous cell carcinoma 2 weeks after the biopsy, and a perineural tumor was noted during the Mohs procedure.
The low number of adverse events encountered in our study supports that in-office compounding of lidocaine preparations is a safe method of providing anesthesia for dermatologic procedures. Furthermore, the adverse event encountered in our study ( paresthesia after biopsy) was more likely due to perineural invasion of the tumor than compounded anesthesia used for biopsy. 4 This retrospective chart review of patients who received anesthesia compounded in-office supports the theory that in-office compounding is a reasonable option for dermatologic procedures.
Requiring pharmacy compounding of local anesthesia would presumably increase costs and would not necessarily confer any benefit to patient safety. 5 In-office compounding helps ensure cost-effective care for our patients. More studies with larger patient samples and various procedure settings are necessary to further support this conclusion and ensure that in-office compounding does not become prohibited by costly and unnecessary regulation.
Atopic dermatitis is not a risk factor for keratoconus: A population-based cohort study
To the Editor: Keratoconus is an eye disorder in which the cornea becomes thin and bulges out in a conical shape. Conflicting results have been reported in the literature regarding whether atopic dermatitis (AD) is associated with keratoconus development.
1,2 So far, only case series have shown an association between AD and keratoconus. 3 Hence, we investigated the risk of keratoconus in young Korean patients with AD by using the National Health Insurance ServiceeNational Sample Cohort database, which includes a random sample of 1,025,340 Koreans with claims made over a 12-year period (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) ). 4 For analysis 1-a longitudinal cohort analysiswe included 34,375 patients with incident AD (16,159 women [47%]) younger than 20 years who (1) had a disease-free period of at least 2 years before the incident date and (2) had at least 1 more AD-related visit and received 1 of the following drugs within a year of the incident date: oral antihistamines, topical corticosteroids, or topical calcineurin inhibitors. Among these, we defined patients with severe AD (3734 cases, including 1571 in women [42%]) as those receiving systemic drug(s) for AD treatment in accordance with established guidelines within a year of the incident date. 5 We matched 4 controls to each patient with AD by using propensity scores based on age, sex, residential area, and household income; 137,500 controls (11,089 controls for severe cases) were matched for the analysis 1 (Fig 1) . There were no significant differences in the incidence probability of newly diagnosed keratoconus between the AD and control groups (0.01% versus 0.04% at 10 years [P ¼ .16]) (Fig 2) or between the severe AD and control groups (0% versus 0.01% at 10 years [P ¼ .31]). After control for age, sex, residential area, household income, and comorbidities, the adjusted hazard ratio of keratoconus was 0.36 (95% confidence interval, 0.08-1.54; P ¼ .17) in the AD cohort and 1.87 (95% confidence interval, 0.43-8.22; P ¼ .41) in the severe AD cohort relative to the control group.
For analysis 2-a nested case-control study-we included 229 patients with incident keratoconus who were younger than 30 years and 2290 controls matched by using propensity scoring as mentioned earlier. We defined a history of AD as the presence of any AD-related visits within 2 years before the keratoconus incident date and patients with severe AD as those receiving systemic drugs during those 2 years. There was no significant difference between the keratoconus and control groups in terms of the proportion of patients with AD (7.0% versus 6.5% [P ¼ .76]) or severe AD (1.8% versus 1.4% [P ¼ .68]) during the 2 years before the incident date.
We could not define eye rubbing as a control variable in eligible subjects; this is an
